Literature DB >> 24408119

Serum potassium in dual renin-angiotensin-aldosterone system blockade.

Stephen L Seliger1, Linda F Fried.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24408119      PMCID： PMC3913249          DOI： 10.2215/CJN.12411213

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  22 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 2.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.

Authors:  Biff F Palmer
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

3.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors:  J N Cohn; G Tognoni
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

4.  Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.

Authors:  Peter N Van Buren; Beverley Adams-Huet; Mark Nguyen; Christopher Molina; Robert D Toto
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

5.  Hyperkalemia and hyporeninemic hypoaldosteronism.

Authors:  R A DeFronzo
Journal:  Kidney Int       Date:  1980-01       Impact factor: 10.612

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

Review 8.  Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?

Authors:  Dick de Zeeuw
Journal:  Kidney Int Suppl       Date:  2004-11       Impact factor: 10.545

9.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

10.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245
View more
  3 in total

Review 1.  Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management.

Authors:  André Gustavo P Sousa; João Victor de Sousa Cabral; William Batah El-Feghaly; Luísa Silva de Sousa; Adriana Bezerra Nunes
Journal:  World J Diabetes       Date:  2016-03-10

Review 2.  Medication Safety Principles and Practice in CKD.

Authors:  Chanel F Whittaker; Margaret A Miklich; Roshni S Patel; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-18       Impact factor: 8.237

3.  The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis.

Authors:  Henrik Laurits Bjerre; Julie B Christensen; Niels Henrik Buus; Ulf Simonsen; Junjing Su
Journal:  J Hum Hypertens       Date:  2019-01-10       Impact factor: 2.877
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.